The newest class of antiretrovirals for all persons living with HIV are the integrase strand
transfer inhibitors (INSTIs). Since 2007, five INSTIs have been introduced: raltegravir …

Abstract Purpose of Review This review focuses on the differential effects of contemporary
antiretrovirals on systemic inflammation as heightened immune activation is linked to …

Context New trial data and drug regimens that have become available in the last 2 years
warrant an update to guidelines for antiretroviral therapy (ART) in human immunodeficiency …

The evolution of human immunodeficiency virus (HIV) treatment has improved our
understanding and management of complex pharmacological issues that have driven …

Background Our objective was to assess therapeutic non-inferiority of dual treatment with
lopinavir–ritonavir and lamivudine to triple treatment with lopinavir–ritonavir plus two …

With the approval in 2007 of the first integrase inhibitor (INI), raltegravir, clinicians became
better able to suppress virus replication in patients infected with human immunodeficiency …

Purpose of review The goal of this paper is to provide an up-to-date review of adverse
events related to the class of integrase strand transfer inhibitors (INSTIs), which became the …

Background Patients with HIV on antiretroviral therapy might benefit from regimen
simplification to reduce pill burden and dosing frequency. We aimed to assess the safety …

Introduction: Increased bacterial translocation and alterations to gut microbiota composition
have been described in HIV infection and contribute to immune activation and inflammation …

Objectives: To estimate the incidence of and risk factors for emergent resistance to integrase
strand transfer inhibitor (INSTI) and nucleoside (-tide) reverse transcriptase inhibitors (NRTI) …